4//SEC Filing
Rottinghaus Scott T. 4
Accession 0001062993-23-022051
CIK 0001177648other
Filed
Dec 5, 7:00 PM ET
Accepted
Dec 6, 8:24 PM ET
Size
5.4 KB
Accession
0001062993-23-022051
Insider Transaction Report
Form 4
Rottinghaus Scott T.
Chief Medical Officer
Transactions
- Sale
Common Stock
2023-12-05$9.63/sh−534$5,142→ 26,466 total
Footnotes (2)
- [F1]Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $9.49 to $9.63, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth set forth in this footnote of this Form 4.
Issuer
ENANTA PHARMACEUTICALS INC
CIK 0001177648
Entity typeother
Related Parties
1- filerCIK 0001942407
Filing Metadata
- Form type
- 4
- Filed
- Dec 5, 7:00 PM ET
- Accepted
- Dec 6, 8:24 PM ET
- Size
- 5.4 KB